|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_001373, 42794009|
|Calculated MW||46090 Da|
|Application Notes||DPAGT1 antibody can be used for detection of DPAGT1 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||DPAGT1; At least four isoforms of DPAGT1 are known to exist; this antibody will recognize the two longest isoforms. DPAGT1 antibody is predicted to not cross-react with UHRF1BP1.|
|Reconstitution & Storage||DPAGT1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||DPAGT1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the initial step in the synthesis of dolichol- P-P-oligosaccharides.|
|Cellular Location||Endoplasmic reticulum membrane; Multi-pass membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DPAGT1 Antibody: The UDP-N-acetylglucosamine-dolichyl-phosphate N-acetyl-glucosaminephosphotransferase (DPAGT1) is an enzyme that catalyzes the first step in the dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis. Mutations in this integral endoplasmic reticulum (ER) membrane protein enzyme belongs to the glycosyltransferase family 4 results in the congenital disorder of glycosylation type Ij with symptoms such as severe hypotonia, medically intractable seizures, mental retardation, microcephaly, and exotropia. Recent experiments have shown that DPAGT1 is a target of the Wnt/beta-catenin signaling pathway, with Wnt3a inducing higher DPAGT1 mRNA expression.
Wu X, Rush JS, Karaoglu D, et al. Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of glycosylation type Ij. Hum. Mutat. 2003; 22:144-50.
Bretthauer RK. Structure, expression, and regulation of UDP-GlcNAc:dolichol phosphate GlcNAc-1-phosphate transferase (DPAGT1). Curr. Drug Targets 2009; 10:477-82
Sengupta PK, Bouchie MP, and Kukuruzinska MA. N-glycosylation gene DPAGT1 is a target of the Wnt/beta-catenin signaling pathway. J. Biol. Chem. 2010; 285:31164-73.
If you have any additional inquiries please email technical services at email@example.com.